Your search for aduhelm returned 38 results

A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...

Federal standards, employer preparedness plans need improving to protect frontline workers: study … Joint federal agency letter urges utility data access for affordable housing providers … LeadingAge...

Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.

Researchers have found a way to deliver Alzheimer’s drugs faster via focused ultrasound technology, a new study shows.

Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...

Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.

A bipartisan group of attorneys general from 23 states have joined a growing chorus calling on Medicare to reverse a previous decision and provide unrestricted coverage of Food and Drug Administration-approved...

Medicare needs to reconsider its national coverage decision on FDA-approved Alzheimer’s drug treatments, bipartisan members of the House told Centers for Medicare & Medicaid Services Administrator Chiquita...

With personal stories of the effects that Alzheimer’s disease has had on them, lawmakers in a Senate Finance Committee hearing on Wednesday called for the federal government to speed up access to treatments....

The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.